What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?
For questions about this article or underlying research, email help@trefis.com.
Pfizer (PFE) stock yields 5.8%, paying holders to wait while the company replaces its older drugs. During its November 3, 2026 call, management named the loss of exclusive rights to Ibrance and Xtandi in the U.S., and to Eliquis outside it, as a key factor for 2027. Management provided only high-level drivers for 2027, and the worry is that those losses arrive faster than the newer drugs grow. So how close are those losses to showing up in Pfizer’s sales?
Pfizer’s Sales Are Holding Steady Before The Patent Losses
Management placed the losses in 2027, and current sales are close to flat. Pfizer posted quarterly revenue of $16.6 billion in fiscal Q3 2026, compared to $16.7 billion a year earlier, as lower sales of COVID-19 products offset growth in non-COVID products. On November 3, management raised the midpoint of its 2026 revenue guide from $61.5 billion to $63 billion.
Management already expects the patent losses to weigh on the balance sheet. Leverage, its debt measured against earnings, should stay around current levels or rise modestly while the patents run out, management said. Pfizer’s 2026 guidance includes no share buybacks.
How Much Room Does Pfizer’s Dividend Have?
Over the twelve months to September 27, 2026, Pfizer generated $11.8 billion in free cash flow, the cash left after capital spending, compared to $9.79 billion paid in dividends. So the patent losses would have to cut free cash flow by about $2.0 billion a year before the business stopped covering its dividend from the cash it brings in.
That makes the risk mainly one for the dividend, not for Pfizer’s ability to pay its debts. Over the same twelve months, operating income covered interest expense 6.1 times. The share price is a separate risk. During the 2023 bond yield shock, from July 25 to December 13, 2023, Pfizer fell 26%, while the S&P 500 lost 9.5%.
Pfizer has newer drugs growing against the losses. Led by Padcev, its launched and acquired products brought in $3.8 billion in fiscal Q3 2026, up 32% by management’s measure. Management said it keeps investing behind these products to offset the patent losses over the next several years. Management also expects to deliver nearly all of $7.2 billion in net cost savings by the end of 2026, and it plans another $2.5 billion from 2027 through 2029.
When Will Pfizer Holders See What Patent Losses Cost?
The first look comes in December. On the November 3 call, management said it will give 2027 guidance around the middle of December, as it did last year. Among drugs still in testing, management expects efficacy results from its SOLIS-1 obesity study in the second half of 2027.
Pfizer is expected to report its fiscal Q4 2026 results in February 2027, which will detail free cash flow and dividends for the full year. That report covers 2026, the year before the losses management placed in 2027, so it sets the baseline. Pfizer’s leverage, 2.6 times at the end of the third quarter, is the figure to compare against once those losses arrive.
Want A Second Look At What You Own?
Pfizer is one decision in a portfolio. Whether you work with an advisor or manage your money yourself, a second look at the whole portfolio costs nothing. Our partner advisory firm offers a free written review of your holdings, fees and income plan, with no need to switch.
Spot an error or want more like this? Tell us in 10 seconds.